The Translational Genomics Research Institute

University of Zürich

Andreas Papassotiropoulos

Dietrich A Stephan

Eric M Reiman

Jennifer Webster

Christopher B Heward

Dominique J-f De Quervain

Dominique J-F De Quervain

The present disclosure relates to genetic markers and methods of diagnosing and screening for late-onset Alzheimer's disease (LOAD). As such, the disclosure encompasses a whole-genome association analysis of single nucleotide polymorphisms (SNPs) of which a number are located within the GRB2-associated binding protein 2 (GAB2) gene as well as other markers associated with other genes. The disclosure identifies two novel haplotypes within the GAB2 gene, i.e., a LOAD risk-enhancing and a LOAD risk-decreasing haplotype. These haplotypes modify LOAD risk differentially in combination with APOE alleles. Further encompassed are therapeutic methods and agents of decreasing the deterioration of cells associated with LOAD.

Methods of diagnosing alzheimer's disease and markers identified by set association

The present invention relates to DNA sequences associated with human memory performance. It also provides methods for (i) screening for diseases and pathological conditions affecting human memory, (ii) identifying agents useful for treatment of diseases and pathological conditions affecting human memory, and (iii) agents and compositions useful for treatment of diseases and pathological conditions affecting human memory.

Genes affecting human memory performance

Growing community of inventors

Zurich, Switzerland

Andreas Papassotiropoulos